Medical Safety
Resume:
CURRICULUM VITAE
Scott Evan Eder, M.D., F.A.C.O.G., F.A.C.S
The Center for Women s Health & Wellness, LLC
*** ********** ****, ****. ***, Suite C
Plainsboro, New Jersey 08536
Office: 609-***-****
Fax: 609-***-****
******@*******.***
1. CERTIFICATION
American Board of Obstetrics & Gynecology Diplomat 1989
Recertified 1997
Recertified 2007
Voluntary Recertification,
2004,2005,2006,2008,2009,2010,2011
Certifying Commission in Medical Management Certified Physician Executive
2001
Association of Pharmaceutical Physicians and Investigators
Certified Physician Investigator
2007
National Certification Corporation Certificate of Added Qualification in
Electronic Fetal Monitoring
2009
2. LICENSURE
Florida ME 99513
Missouri 36473
New Jersey MA43626
New York 163424 (inactive)
Pennsylvania MD-041421E
3. EDUCATION
A. Undergraduate
1970-1974 B.A., History
Boston University
Boston, Massachusetts
Scott E. Eder, M.D., F.A.C.O.G., F.A.C.S. 1
B. Graduate and Professional
1974-1976 M.S., Physiology
Rutgers University
New Brunswick, New Jersey
1976-1982 Doctor of Medicine
Universite Catholique de Louvain
Brussels, Belgium
1998-2000 M.S., Administrative Medicine,
University of Wisconsin Medical School
Madison, Wisconsin
4. POSTDOCTORAL TRAINING
Internship and Residency
1982-1983 Department of Internal Medicine
St. Louis University Group Hospitals
St. Louis, Missouri
1983-1987 Department of Obstetrics & Gynecology
UMDNJ-New Jersey Medical School
Newark, New Jersey
5. UNIVERSITY APPOINTMENTS
1983-1987 Clinical Instructor II
UMDNJ-New Jersey Medical School
Newark, New Jersey
1988-1992 Clinical Instructor
UMDNJ-New Jersey Medical School
Newark, New Jersey
1992-2005 Clinical Assistant Professor
2008-2009 Department of Obstetrics/Gynecology
UMDNJ-New Jersey Medical School
Newark, New Jersey
Scott E. Eder
M.D., F.A.C.O.G., F.A.C.S. 2
6. HOSPITAL APPOINTMENTSJuly 1987-December 1987St. Mary s Hospital
Good Samaritan Hospital
Humana Hospital
Wellington Regional Medical Center
Palms West Hospital
West Palm Beach, Florida
February 1988-presentCapital Health System
Trenton, New Jersey
October 1988-2005UMDNJ-University Hospital
Newark, New Jersey
July 1989-presentUniversity Medical Center at Princeton
Princeton, New Jersey
September 1994-2003Robert Wood Johnson Medical Center
At Hamilton
Trenton, New Jersey
7. OTHER PROFESSIONAL POSITIONS
1984-1987Clinician
Planned Parenthood of Bergen County
Hackensack, New Jersey
1988-1990Clinician
Planned Parenthood of Mercer County
Trenton, New Jersey
1989-1991Clinician
Rutgers Community Health Plan
Lawrenceville, New Jersey
1989-1991Medical Director
1995-1996Familyborn Birth Center
Princeton, New Jersey
1994-1997Producer and Host,
Healthcare Radio Show
New Jersey Network
Trenton, New Jersey
Scott E. Eder, M.D., F.A.C.O.G., F.A.C.S. 3
2006-presentPhysician-Medical Missions to Niger and Rwanda
International Organization for Women &
Development, Inc.
Rockville Centre, New York
2011-presentMedical ConsultantEverett Laboratories, Inc.
29 Spring Street
West Orange, New Jersey
8. AWARDS AND HONORS
1992, 1995, 1998, 2001, AMA Physician s Recognition Award
2004, 2007
9. BOARD OF DIRECTOR/TRUSTEES
1992-2001Associate Board of GovernorsCapital Health System
Trenton, New Jersey
1993-presentBoard of Trustees
Mercer County Medical Society
Trenton, New Jersey
10. MAJOR COMMITTEE ASSIGNMENTS
a. National and Regional
One Health Plan of NJ, Inc Southern Physician Advisory
One Centennial Avenue Committee
Piscataway, NJ 08855 2001-present
Empire Blue Cross/BS Practice Guidelines Subcommittee
Wellchoice Inc. 2000-2001
nd
11 West 42 Street Clinical Quality Committee
New York, NY 10036 2003-present
Physician s Healthcare Plan of NJ Credentials Committee
Lawrenceville, New Jersey 1995-1997
Scott E. Eder, M.D., F.A.C.O.G., F.A.C.S. 4
b. Hospital
Helene Fuld Medical Center Chairman, Medical Records
(Capital Health System) 1991-1996
Continuing Medical Education1989-1990Credentials
1992-2000
Operations and Other Procedures
2000-2003. Chairman, 2002
Medical Center at Princeton Credentials
2000-2008
c. Departmental
Helene Fuld Medical Center
Secretary, Ob/Gyn 1991-1992
Vice Chairman, Ob/Gyn1994-1995
Chairman, Ob/Gyn1995-1997
11. MEMBERSHIP IN PROFESSIONAL SOCIETIES
American College of Obstetricians & Gynecologists- Fellow
American College of Surgeons- Fellow
American Medical Association
New Jersey Medical Society
Mercer County Medical Society- President, 2004-2005
Association of Clinical Research Professionals
Drug Information Association
American College of Physician Executives
Scott E. Eder
M.D., F.A.C.O.G., F.A.C.S. 5
12. GRANT HISTORY
Rhone-Poulenc Rorer (RPR 106522-201) Principal Investigator, A Randomized,
Double-blind, Multi-Center Progestin Efficacy Study of Thee Doses of RPR
Estradiol/Norethisterone Acetate (NETA) Patches in Sequential Wear HRT Regimen
Compared to an Estradiol 50 Patch 1994
Ortho-McNeil Pharmaceutical, Inc. (CAPSS-062) Principal Investigator, Effect of an
Extended Pill-Free Interval on Follicular Activity, OrthoTricyclin and Alesse, 1997 -
1998
Ortho-McNeil Pharmaceutical, Inc. (CAPSS-053) Principal Investigator, Time to
Symptomatic Relief: Terazol 3 Vaginal Cream Vs. Diflucan, 1998
Berlex (Protocol 96043) Principal Investigator, A Multicenter, Double-Blind
Randomized Study of Continuous Transdermal Estradiol-Levonorgesterol Combination,
Compared to Continuous Transdermal Estradiol to Examine the Safety and Effects on
Endometrium, Symptoms, and Bleeding Patterns in Post Menopausal Women, 1998-
1999
Searle (N6S-97-02-001) Principal Investigator, Dosing Optimization with Intranasal
Synarel (Naferelin Acetate) for Patients with Endometriosis, 1999
Ortho-McNeil Pharmaceutical, Inc. (CAPSS-153) Principal Investigator, A Multicenter,
Randomized, Open-Label, Parallel Group Study to Evaluate the Endometrial Safety
Following Treatment with Ortho-Prefest Compared to Prempro in Postmenopausal
Women, 2001
Ortho-McNeil Pharmaceutical, Inc. (CAPSS-320) Principal Investigator, Comparison of
the Safety and Efficacy of Patient Controlled Analgesia Delivered by Fentanyl HCl
Transdermal System Versus Morphine IV Pump for Pain Management after Non-
emergent Lower Abdominal or Pelvic Surgery, 2004-2005
Novo Nordisk Pharmaceuticals, Inc. (VAG-2195) Principal Investigator, A 12 month
double-blind, randomized, parallel-group, placebo controlled, multicenter trial to
investigate the efficacy and safety of Vagifem Low Dose (10microgram 17 beta estradiol
vaginal tablet) for the treatment of postmenopausal atrophic vaginitis symptoms, 2005
Duramed Research Inc. (DR-MPG-201) Principal Investigator, A Phase II, Multicenter,
Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Induction of
Withdrawal Bleeding After Administration of Oral Micronized Progesterone in Women
with Secondary Amenorrhea 2005
Duramed Research Inc. (DR-PSE-309) Principal Investigator, A Multicenter, Open-
Label Study to Evaluate the Efficacy and Safety of an Extended Cycle, Low Dose,
Combination Oral Contraceptive Regimen, DP3-Lo84/10, Which Utilizes Ethinyl
Estradiol During the Seven Day Interval Between Each 84-day Cycle of Combination Therapy
For the Prevention of Pregnancy in Women 2005
Scott E. Eder, M.D., F.A.C.O.G., F.A.C.S. 6
Luitpold Pharmaceuticals, Inc. (1 VIT 03001) Principal Investigator, Comparison of the
Safety and Efficacy of a Unique Intravenous Iron Preparation (Vit 45) versus Oral Iron in
Subjects Who Display Post Partum Anemia 2005
Church & Dwight Co. Inc. (ST-6981) Principal Investigator, Analytical Accuracy Test
to Evaluate Percent Agreement Between a Male Fertility Diagnostic Device and Manual
Sperm Analysis 2006
Wyeth Pharmaceuticals Inc. (3115A1-304-WW) Principal Investigator, A Double-Blind,
Randomized, Placebo and Active Controlled Efficacy and Safety Study of
Bazedoxifene/Conjugated Estrogens Combinations for Prevention of Endometrial
Hyperplasia and Prevention of Osteoporosis in Postmenopausal Women 2006
Organon USA Inc. (292002) Principal Investigator, A Randomized, Open Label,
Comparative, Multi-Center Trial To Evaluate Contraceptive Efficacy, Cycle Control,
Safety And Acceptability Of A Monophasic Combined Oral Contraceptive (COC)
Containing 2.5 Mg Nomegestrol Acetate (NOMAC) and 1.5 Mg Estradiol (E2),
Compared To A Monophasic COC Containing 3 MG Drospirenone (DRSP) and 30
Micrograms Ethinyl Estradiol (EE) 2006Church & Dwight Co. Inc. (ST-7005) Principal Investigator, An Observational Study to
Evaluate the Safety and Ease of Self-vaginal Specimen Collection by Untrained
Consumers for Intended OTC Diagnosis of Bacterial Vaginosis (BV) and Yeast Infection
(YI,) 2006
Duramed Research Inc. (DR-CEN-302) Principal Investigator, A Randomized,
Multicenter, Double-blind, Placebo-Controlled Trial to Compare the Effects of 12 Weeks
of Treatment with Cenestin Vaginal Cream vs. Placebo Vaginal Cream on Vulvovaginal
Atrophy in Healthy Postmenopausal Women, 2006
Xanodyne Pharmaceutical Inc. (XP12B-MR-303) Principal Investigator, A Randomized,
Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate
Efficacy And Safety of 1.3g Oral Doses of XP12B-MR TID During Menstruation For
The Treatment of Menorrhagia, 2006
Symbollon Pharmaceuticals, Inc. (Protocol 005) Principal Investigator, A Phase III,
Multicenter, Randomized, Double Blind, Placebo-Controlled Study of IoGen for the
Treatment of Moderate or Severe, Periodic Breast Pain Associated with Symptomatic
Fibrocystic Breast Disease in Otherwise Healthy, Euthyroid, Premenopausal Women,
2006Hormos Medical Ltd. (Protocol 15-50310) Principal Investigator, Efficacy and Safety of
Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal
Women: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group
Study Comparing Oral Ospemifene 30 mg and 60 mg Daily Doses With Placebo, 2006
Medicis Pharmaceutical Corporation (MP-0104-18) Principal Investigator, A
Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of
Minocycline Extended-Release Tablets on Spermatogenesis in Human Males, 2007
Scott E. Eder, M.D., F.A.C.O.G., F.A.C.S. 7
Duramed Research Inc. (Protocol DR-DSG-302) Principal Investigator, A Prospective,
Multicenter, Randomized, Double-blind Study to Evaluate Hormone Patterns and
Ovarian Follicular Activity with the Oral Contraceptive Regimen DR-1021, 2007
TriPath Imaging, Inc. (Protocol MP-3-01) Principal Investigator, Intended Use Study of
the SurePath Molecular Pap, 2007
Xanodyne Pharmaceutical Inc. (Protocol XP12B-MR-301) Principal Investigator, A
Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to
Evaluate Efficacy and Safety of 0.65g and 1.3g Oral Doses of XP12B-MR TID
Administered During Menstruation for the Treatment of Menorrhagia, 2007
Warner Chilcott (Protocol PR-05806) Principal Investigator, An Open Label Study of
the Safety and Efficacy of a New Low Dose Oral Contraceptive Containing
Norethindrone Acetate and Ethinyl Estradiol, 2007
Repros Therapeutics, Inc. (Protocol ZPE-201) Principal Investigator, A Phase II, Three-
Arm, Parallel Design, Dose-Ranging, Placebo-Controlled, Randomized, Double-Blind,
Multicenter Study Evaluating the Safety and Efficacy of the Selective Progesterone
Receptor Modulator Proellex (CDB-4124) in the Treatment of Premenopausal Women
with Symptomatic Endometriosis, 2007
TriPath Imaging Inc., (Protocol TriPath 2007-2009) Principal Investigator, Pre-Clinical
Evaluation of a Panel of Biomarkers in the Differential Diagnosis of Ovarian Cancer in
Patients with Abnormal Pelvic Mass, 2008
FemmePharma Global Healthcare, Inc., (Protocol FP1198-001) Principal Investigator, A
Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Evaluation
of the Use of Topically Administered Danazol versus Placebo in Subjects with pain
associated with Fibrocystic Breast Disease, 2008
Bayer Healthcare Pharmaceuticals Inc., (Protocol 310184) Principal Investigator, A
multicenter, double-blind, randomized, placebo-controlled study to determine the lowest
effective dose of oral Angeliq (drospirenone 0.5 mg/17 beta estradiol 0.5mg,
drospirenone 0.25mg/17 beta estradiol 0.3mg) for the relief of moderate to severe
vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks,
2008Roche Molecular Systems, Inc., (Protocol MWP-HPV-159) Principal Investigator,
Evaluation of the Amplicor HPV Test and the Linear Array High Risk HPV Genotyping
Test for the Detection of High-Grade Cervical Disease in Women Undergoing Routine
Cervical Cancer Screening Using Cervical Samples Prepared with the cobas x421
Instrument, 2008
Graceway Pharmaceuticals LLC., (Protocol GW01-0805) Principal Investigator, A
Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and
Safety Study of Imiquimod Creams in the Treatment of External Genital Warts, 2008
KV Pharmaceutical Company, (Protocol CBC-303-***-******) Principal Investigator,
A Randomized, Double-Blind, Parallel-Group Study to Compare the Safety and
Scott E. Eder, M.D., F.A.C.O.G., F.A.C.S. 8
Efficacy of Clindamycin/Butoconazole Vaginal Cream with Butoconazole Alone in the
Treatment of Mixed Bacterial Vaginosis/Vulvovaginal Candidiasis Infections, 200 8
QuatRx Pharmaceuticals Company, (Protocol 15-50821) Principal Investigator, Efficacy
and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and
Vaginal Pain Associated with Sexual Activity, Symptoms of Vulvar and Vaginal Atrophy
(VVA), Associated with Menopause: A 12-Week, Randomized, Double-Blind, Placebo-
Controlled, Parallel Group Study Comparing Oral Ospemifene 60mg Daily Dose With
Placebo in Post Menopausal Women, 2008
OraSure Technologies, Inc., (Protocol OQ-HCV-F-8) Principal Investigator, Clinical
Investigation to Evaluate the Performance of the OraQuick Rapid HCV Antibody Test,
2008
Ferring Pharmaceuticals, (Protocol FPI GNRH2008-03) Principal Investigator, A
Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled Study to
Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered
from a Iontophoretic Patch (Lutrepatch) Compared to Oral Treatment with Clomiphene
Citrate or Placebo in Anovulatory or Oligoovulatory Infertile Females, 2009
Bayer HealthCare Pharmaceuticals, Inc., (Protocol 91555) Principal Investigator,
Multicenter, Open-label, Uncontrolled Study to Investigate the Efficacy and Safety of
the Transdermal Contraceptive Patch Containing 0.55mg Ethinyl Estradiol and 2.1mg
Gestodene in a 21-day Regimen for 13 Cycles in 1650 Healthy Female Subjects 2009
Church and Dwight Co. Inc., (Protocol #246) Principal Investigator, Collection of Urine
Samples From Pregnant Women with Defined Prenatal Gender, 2009
Church and Dwight Co. Inc., (Protocol #270) Principal Investigator, Collection of Early
Pregnancy Urine Samples, 2009
Church and Dwight Co., Inc., (Protocol #279) Principal Investigator, Collection of Urine
Samples from Non-Pregnant Females of Reproductive Age Around Time of Expected
Period. 2009
Duramed Research, Inc., (Protocol #DR-103-301) Principal Investigator, A Multicenter,
Open-Label Study to Evaluate The Efficacy and Safety of A Combination Oral
Contraceptive Regimen For The Prevention Of Pregnancy In Women, 2009
Graceway Pharmaceuticals, LLC, (Protocol # GW05-0904) Principal Investigator, A
Multicenter, Randomized, Investigator-Blinded, Phase 2, Dose Ranging Study of
Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis, 2010
Church and Dwight Co., Inc., (Protocol ST-7329) Principal Investigator, Analytical
Accuracy Test to Evaluate Percent Agreement Between a Male Fertility Diagnostic Test
Device and Manuel Semen Analysis, 2010
Church and Dwight Co., Inc., (Diagnostics Protocol 318) Principal Investigator,
Preliminary Evaluation of Various Optical Measurement Methodologies for Semen
Analysis, 2010
Scott E. Eder, M.D., F.A.C.O.G., F.A.C.S. 9
Boehringer-Ingelheim Pharmaceuticals, Inc., (Protocol 511.156) Principal Investigator,
A Twenty-four Week, Randomized, Double-blind, Placebo Controlled, Safety and
Efficacy Trial of Flibanserin, with Up-titration, 100 Milligrams Administered Orally
Once Daily in Naturally Postmenopausal Women with Hypoactive Sexual Desire
Disorder in North America, 2010
Warner Chilcott Company LLC, (Protocol PR-00110.0) Principal Investigator, Effect of
Udenafil on Spermatogenesis: A Double-blind, Randomized, Placebo-controlled,
Parallel-group Study, 2010
Church & Dwight Co. Inc, (Protocol ST-7356) Principal Investigator, Accelerated
Aging of the First Response Male Fertility Test, 2010
Vermillion, Inc., (Protocol OVA2-001-C03) Principal Investigator, Marker Discovery
and Clinical Trial Testing for OVA2 using Serum From Women with a Documented
Ovarian Adnexal Mass, 2010
Gynuity Health Projects, Principal Investigator, Vaginal and Rectal Clostridial Carriage
Among Women of Reproductive Age In The United States, 2011
Teva Branded Pharmaceutical Products R & D, Inc., (Protocol PSE-HSP-203) Principal
Investigator, A Multinational, Multicenter, Randomized, Open -Label Study to Evaluate
the Impact of a 91-day Extended Cycle Oral contraceptive Regimen, Compared to two
28-day Standard Oral Contraceptive Regimens, on Hemostatic Parameters in Healthy
Women, 2011
Warner Chilcott (US), LLC, (Protocol PR-04409) Principal Investigator, A
Randomized, Double-Blind, Placebo-Controlled Comparison of Two Dosing Regimens
of a Low Dose Estradiol Vaginal Cream With Regard to Their Safety and Efficacy in the
Treatment of Symptoms of Vaginal Atrophy in Postmenopausal Women, 2011
Emotional Brain New York LLC, (Protocol EB 82) Principal Investigator, Lybrido At
Home: A Double Blind, Randomized, Placebo-Controlled Dose-Finding Study to
Investigate the Efficacy of Lybrido in Healthy Female Subjects with Hypoactive Sexual
Desire Disorder (HSDD) and Low Sensitivity for Sexual Cues, (2011)
Abbott Laboratories, (Protocol M12-663) Principal Investigator, A Phase 2a Proof of
Concept Study to Evaluate the Safety and Efficacy of Elagolix in Pre-Menopausal
Women with Heavy Uterine Bleeding and Uterine Fibroids, (2011)
Scott E. Eder, M.D., F.A.C.O.G., F.A.C.S. 10
13. MAJOR ADMINISTRATIVE RESPONSIBILITIES
1986-1987Chief ResidentDepartment of Ob/Gyn
UMDNJ-New Jersey Medical School
Newark, New Jersey
1991-2009Managing PartnerDelaware Valley Ob/Gyn and Infertility Group, P.C.
Lawrenceville, New Jersey
1995-1997ChairmanDepartment of Obstetrics & GynecologyHelene Fuld Medical Center
Trenton, New Jersey
1998-presentPresidentWomen s Health Research Center
Plainsboro, New Jersey
2004-2005PresidentMercer County Medical Society
Ewing, New Jersey
14. PRIVATE PRACTICE
July 1987-December 1987 1897Palm Beach Lakes Blvd.
West Palm Beach, Florida
February 1988-September 2009 2 Princess Road, Suite C
Lawrenceville, New Jersey
September 2009-present 666 Plainsboro Road
Plainsboro, New Jersey
Scott E. Eder, M.D., F.A.C.O.G., F.A.C.S. 11
15. MAJOR TEACHING EXPERIENCE
Instruction to junior residents and medical students in obstetrics and gynecology and
family practice.
Lecturer and trainer to physician audiences for major pharmaceutical companies
including Organon, Warner Chilcot, Ortho-McNeil, Lilly, Merck, and Rhone-Poulenc-
Rorer.
Producer and Host, Healthcare Radio Show, New Jersey Network, New Jersey s state
sponsored public broadcasting station, offering the public a weekly half hour call in,
drive time healthcare show highlighting the latest developments in medicine.
BIBLIOGRAPHY
Scott E. Eder
M.D., F.A.C.O.G., F.A.C.S. 13
Contact this candidate